To send content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about sending content to .
To send content items to your Kindle, first ensure email@example.com
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about sending to your Kindle.
Note you can select to send to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Early detection and aggressive chemotherapy/radiotherapy treatments have improved the long-term survival rates for many young women with various types of cancer. As a consequence of these cytotoxic treatments, their reproductive future can be either short lived or eradicated. For young single women with cancer, oocyte cryopreservation offers the best potential option for achieving a future pregnancy using their own gametes. Unfortunately, the urgent need to commence cytotoxic treatment often does not permit adequate time for cryopreservation of mature oocytes. Conversely, cryopreservation of ovarian tissue eliminates the delay necessary to obtain mature oocytes, but the subsequent potential for establishing pregnancy is currently unknown. Although ovarian tissue cryopreservation is an attractive alternative and frequently used for patients with these conditions, little has been published on the efficacy of various protocols. Cryopreservation of ovarian tissue is more complex than that of gametes or embryos, requiring preservation of multiple cell types, which may vary in volume and water permeability. Essentially, ovarian tissue cryopreservation is more similar to organ cryopreservation than to that of gametes or embryos.
This chapter focuses on patients with testicular cancer and lymphoma that generally affects younger patients in the reproductive window with an excellent overall survival. The chance of recovery of spermatogenesis depends on the chemotherapeutic regimen as well as the baseline function of the patient. The existence of a previously cryopreserved sperm greatly simplifies the algorithm for the post chemotherapeutic azoospermic man and, essentially, the couple can go directly to in vitro fertilization (IVF). Azoospermia after chemotherapy can be due to the patient's chemotherapeutic regimen, the use of radiation, the extent of surgery, the disease itself, the baseline function of the patient or any combination of the aforementioned factors. Additional counseling is recommended for those patients who choose the assistance of third-party reproduction. Gamete donation has made it possible for participants to cross generational lines and has raised many complicated ethical issues.
Pregnancies and live births from human cryopreserved in vitro fertilization (IVF) embryos provide proof of principle and lead to the adoption of embryo cryopreservation as a routine adjunct to IVF and embryo transfer (IVF/ET). Embryo cryopreservation is an essential tool when embryo transfer is not possible in the cycle of oocyte collection. The widely accepted criterion for embryo survival and eligibility for transfer in a clinical situation is that a minimum of 50% of the original blastomeres survive. Human embryos can be successfully cryopreserved using a range of techniques at all stages of development and can result in the birth of normal, healthy children when transferred back to the uterus. Application of this technology in the context of infertility treatment has had a major impact on the development of more conservative approaches to the number of embryos transferred and the overall cumulative efficiency of treatment.